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Abstract
The evolution of drug resistance in HIV occurs by the fixation of specific, well-
known, drug-resistance mutations, but the underlying population genetic pro-
cesses are not well understood. By analyzing within-patient longitudinal se-
quence data, we make four observations that shed a light on the underlying
processes and allow us infer the short-term effective population size of the vi-
ral population in a patient. Our first observation is that the evolution of drug
resistance usually occurs by the fixation of one drug-resistance mutation at a
time, as opposed to several changes simultaneously. Second, we find that these
fixation events are accompanied by a reduction in genetic diversity in the region
surrounding the fixed drug-resistance mutation, due to the hitchhiking effect.
Third, we observe that the fixation of drug-resistance mutations involves both
hard and soft selective sweeps. In a hard sweep, a resistance mutation arises in
a single viral particle and drives all linked mutations with it when it spreads in
the viral population, which dramatically reduces genetic diversity. On the other
hand, in a soft sweep, a resistance mutation occurs multiple times on different
genetic backgrounds, and the reduction of diversity is weak. Using the frequency
of occurrence of hard and soft sweeps we estimate the effective population size
of HIV to be 1.5 × 105 (95% confidence interval [0.8 × 105, 4.8 × 105]). This
number is much lower than the actual number of infected cells, but much larger
than previous population size estimates based on synonymous diversity. We
propose several explanations for the observed discrepancies. Finally, our fourth
observation is that genetic diversity at non-synonymous sites recovers to its pre-
fixation value within 18 months, whereas diversity at synonymous sites remains
depressed after this time period. These results improve our understanding of
HIV evolution and have potential implications for treatment strategies.
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Author Summary
It is well known that HIV can evolve to become drug resistant if it acquires
specific drug-resistance mutations, but the underlying population genetic pro-
cesses are not well understood. We found that the evolution of drug resistance
in HIV populations within infected patients occurs by one mutation at a time
(as opposed to multiple mutations simultaneously) and involves both hard and
soft sweeps. In a hard sweep, a mutation originates in a single viral particle and
then spreads to the entire viral population within the patient. As this mutation
increases in frequency, other mutations linked to it hitchhike to high frequen-
cies, which greatly reduces genetic diversity in the population. In a soft sweep,
on the other hand, the same resistance mutation originates multiple times on
different genetic backgrounds, and hitchhiking may have very little or no effect
on diversity. The fact that drug resistance evolves by means of both hard and
soft sweeps implies that the HIV populations are limited by the supply of re-
sistance mutations. Using the frequency of hard and soft sweeps we obtain a
point estimate of 150,000 for the effective population size of the virus, a number
that is much higher than estimates based on diversity at neutral (synonymous)
sites, but much lower than the actual number of HIV infected cells in a human
patient.
Introduction
Understanding the process of adaptation is one of the basic questions in evolu-
tionary biology. The evolution of drug resistance in pathogens such as HIV is
a prime example of adaptation and a major clinical and public health concern
because it leads to treatment failures.
The likelihood that a population adapts in response to an environmental
challenge, e.g., a viral population in a patient develops resistance in response
to a drug treatment, depends, among other things, on the amount of genetic
diversity that the population harbors [1, 2]. The amount of genetic diversity
in a population depends in turn on the details of the adaptive process. In
the classical model of adaptation, a beneficial mutation arises once in a single
individual and, as this mutation increases in frequency in the population, other
mutations “hitchhike” with it to high frequency [3]. In this process, referred to
as a “hard selective sweep”, genetic diversity at linked sites is strongly reduced
when the beneficial mutation fixes in the population. However, if the population
is sufficiently large, beneficial mutations will occur frequently or will be present
in multiple copies prior to the onset of selection. Then, multiple beneficial alleles
may replace the wildtype without leading to a significant reduction in diversity.
This is called a “soft selective sweep” [4].
We use HIV as a model system to ask the following evolutionary questions.
How much do selective sweeps affect genetic diversity at neighboring sites?
How often does adaptation occur via soft and hard sweeps? What is the ef-
fective population size of HIV relevant for adaptation (later referred to simply
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as Ne)? How does diversity recover after a selective sweep at synonymous and
non-synonymous sites? Three factors make HIV well suited to address these
questions: (a) HIV evolves rapidly due to its short replication time and high
mutation rate, (b) HIV populations in different patients act as independent
replicates of the same evolutionary process, and (c) the main genetic targets of
positive selection in HIV during antiviral treatment are known: these targets
are drug-resistance mutations which have been well characterized.
From the questions above, the estimation of the short-term effective popula-
tion size (Ne) of HIV is perhaps the most interesting and clinically important.
We are interested in the short-term effective population size because it is one
of the determinants of the probability that drug resistance evolves in a certain
generation. This effective population size is primarily determined by current
processes (such as possibly background selection), and much less so by histor-
ical processes or events (such as bottlenecks). The question of the effective
population size of HIV has been a subject of a heated debate because of enor-
mous discrepancies in the estimates obtained by different methods (see [5] for
a review). In an influential 1997 paper, Leigh-Brown used genetic diversity at
synonymous sites and estimated the effective size of the viral population to be
on the order of 103 [6]. Around the same time, it became clear that the number
of active virus-producing cells in the body of an infected person was around
108 [7] which lead to a natural expectation that the viral population should
be very large with almost deterministic evolutionary dynamics [8]. However,
Frost et al found that frequencies of resistance mutations before the start of
treatment varied greatly between patients, which led them to conclude that
stochastic effects play an important role in HIV, and the population size must
therefore be 106 or smaller [9]. With more data and a more sophisticated linkage
disequilibrium-based method Rouzine and Coffin inferred that the population
size of the virus must be at least 105 [10]. Finally, a recent study by Maldarelli
et al [11] places Ne between 10
3 and 105, based on changes in allele frequencies
over time.
We estimate Ne of HIV using previously published longitudinal sequence
data from several HIV-infected patients under drug treatment [12]. Our ap-
proach to estimating Ne is most closely related to the recent estimates done in
Drosophila [13], Plasmodium [14], and a chimeric simian-human immunodefi-
ciency virus [15], but differs from these studies in that we use data from several
patients for increased statistical power. The main idea of our method is as fol-
lows. Since the mode of adaptation (hard versus soft sweeps) depends on the
supply of beneficial mutations which in turn depends on the effective size of the
population, it is possible to use the observed frequency of hard and soft sweeps
to estimate Ne. The key problem is to distinguish hard and soft sweeps in the
sequence data. We address this problem by taking advantage of a unique prop-
erty of codon 103 in the reverse-transcriptase gene, namely that there are two
distinct nucleotide changes that convert the (wildtype) amino acid lysine into
asparagine, which confers drug resistance. If both of these nucleotide changes
are observed in a single sample, a soft sweep must have occurred.
While the effects of selection and demographic processes on the reduction
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of diversity have been extensively studied, the question of how diversity recov-
ers after perturbations has received little attention. Yet, understanding the
dynamics of recovery is important because it determines how long signatures
of selective sweep or bottlenecks remain detectable in genetic data. Failure to
account for the time it takes for diversity to reach its equilibrium after a pertur-
bation can lead to biases in estimation of population genetic parameters such
as Ne [5]. Using longitudinal data we show here that diversity after a selective
sweep recovers faster at non-synonymous sites than at synonymous sites.
Results and Discussion
Selective sweeps reduce genetic diversity
We study how the genetic composition of HIV populations in patients treated
with a combination of reverse transcriptase (RT) and protease inhibitors changed
over the course of about one year (see Ref. [12] and Loss of diversity for details
on the data). Out of 118 patients studied in Ref. [12], we selected a subset of 30
patients in which the virus had no resistance mutations at the start of the study
but fixed a resistance mutation at one of the later time points. All our analyses
were done on this subset of patients (see Loss of diversity for details). We
note that in 24 out of 30 patients (80%) we detect fixation of a single resistance
mutation within the observation period, even though all patients were treated
with multiple drugs (see Suppl Table S1).
Samples taken prior to treatment in these patients show nucleotide diversi-
ties of ∼ 3% at synonymous sites and < 1% at non-synonymous sites. At the
time points when we detect fixations of drug-resistance alleles at one or several
known sites we observe a substantial decrease in the levels of polymorphism in
the 1Kb region that was sequenced (see Figures 1, 2, 3, and Loss of diver-
sity). Between the last sample before and the first sample after the fixation of
the first drug-resistance mutation, viral populations lose 53% of their genetic di-
versity, measured by the median drop in per-site heterozygosity. This difference
is significant, with P < 10−3 (all P-values we report are from Mann-Whitney
tests). We observe no loss of diversity in control intervals in which no resistance
mutation was fixed (see Loss of diversity).
The loss of diversity that we observe is a result of hitchhiking: when an
adaptive mutation rapidly increases in frequency, it takes with it the genetic
background on which it arose [3]. Three factors can attenuate the observed
loss of diversity after a sweep. First, recombination can preserve some diversity
by allowing sites at some distance from the selected site to escape the effects
of the sweep [16]. Recombinational escape does not appear to be a factor in
these data however because we do not observe a correlation between post-sweep
heterozygosity and distance from the selected site (see Recombination). This
is consistent with previously reported observations in HIV [17].
Second, the amount of diversity lost depends on the origin of the adaptive
allele. Diversity may survive the fixation of an adaptive allele even in the absence
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of recombination if the selective sweep is “soft”, i.e., if the same adaptive allele
arises via multiple mutations on different genetic backgrounds [18]. On the
other hand, genetic diversity at neighboring sites is reduced dramatically if the
selective sweep is “hard”, i.e., if the adaptive allele originates through a single
mutation on one genetic background [3]. We demonstrate below that both
soft and hard sweeps occurred in these patients. Importantly, whether soft or
hard sweeps predominate in a population depends on the supply of adaptive
mutations which is determined by the product of the beneficial mutation rate
and the current effective population size. If adaptive mutations appear in the
population on average more than once per viral generation, they are likely to
fix via soft sweeps. If adaptive mutations appear on average less than once
per generation, they typically fix via hard sweeps [4]. Thus, we can assess
the supply rate of resistance mutations by determining whether the observed
selective sweeps are soft or hard.
Third, the observed loss of diversity depends on whether new mutations
occur between the fixation of a resistance allele and the time when samples
are taken and the sweep is observed. Since we do not know the actual time
of fixation, we do not know the absolute amount of diversity loss due to the
sweep. However, this fact does not obscure informative patterns of relative
loss of diversity, for synonymous versus non-synonymous mutations and for soft
versus hard sweeps.
Estimating Ne from the frequency of soft sweeps
In 17 of the 30 HIV populations (57%), we observe the fixation of just one,
well-known drug resistance mutation, K103N (lysine to asparagine) in RT. This
mutation confers high-level resistance to the non-nucleoside RT inhibitor used
by the patients [12]. Two different nucleotide changes produce the same K103N
amino acid change. The wildtype codon AAA encoding lysine can mutate to
either codon AAC or codon AAT both encoding asparagine which confers re-
sistance. This property is unique to the K103N mutation among all resistance
mutations observed in these patients (see Suppl. Table S1) and can be used
to distinguish soft and potentially hard sweeps.
In 7 of these 17 populations (41%) both codons (AAC and AAT) that code
for asparagine are present in the population in the first sample after the sweep
(Figure 1). These are certain to be soft sweeps. As expected, the median
reduction of diversity in these populations is only 15% and not significantly
different from 0. In the remaining 10 patients (59%) only one codon is present
after the sweep (AAC in 6 and AAT in 4 patients; Figure 2). These sweeps
could be either soft or hard. If in these 10 “one-codon” patients the resistance
allele typically arose via the same number of unique mutation events as in the
7 “two-codon” patients, we would expect to see a similarly small reduction in
diversity at linked sites in these two groups of patients. In contrast, we find
that in the 10 “one-codon” viral populations, genetic diversity is reduced by
71% (P = 0.003), and the difference between the “two-codon” and “one-codon”
populations is significant (P = 0.007). It is possible that two codons initially
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fixed in the “one-codon” patients but one of the codons was lost (for example,
due to another sweep) before the sample was taken. This scenario would have
been plausible if the time intervals between samples were, for some reason, longer
in the “one-codon” than in the “two-codon” patients. However, we observe no
statistical difference in the inter-sample time intervals between the “two-codon”
and “one-codon” patients (P = 0.48). We therefore conclude that the selective
sweeps in the “one-codon” patients are due to fewer mutational origins than in
the “two-codon” patients, and some are likely hard sweeps (see Figure 2).
The fact that we observe both soft and hard sweeps implies that the K103N
mutation appears roughly once per generation [4]. A more accurate estimate
of the mutation supply rate θ/2 based on the frequencies of AAC and AAT
alleles in the post-sweep samples yields θ/2 = 0.3 new K103N mutations per
generation (95% confidence interval [0.17, 0.97]). Assuming that we sample 6
viral isolates per patient (which is the median in our dataset), theory predicts
that, if θ/2 = 0.3, 30% of populations would show a hard sweep signature
(i.e., the sweep would be due to a single origin), which is consistent with our
observations. Assuming the point mutation rate of 2× 10−6 per generation for
transversions [19], we estimate the effective population size of HIV populations
to be Ne = 1.5 × 105 [0.8 × 105, 4.8 × 105] (see Estimating the supply rate
of resistance mutations for details).
We estimated Ne based on data from the 17 patients in which the K103N
mutation fixed. Although we cannot do the same analysis with the other resis-
tance mutations in the dataset, we find that the median reduction in diversity in
the other 13 patients is intermediate between the “one-codon” and “two-codon”
K103N patients (see Suppl. Figure S1), which suggests that K103N mutation
is not special and that similar processes are taking place at the other resistance
sites. Further, the haplotype structures in two patients with amino-acid changes
in the 190th codon position suggest a soft sweep in one and a hard sweep in
the other (see Suppl. Figure S2). Thus adaptation at the 103rd codon position
appears to be representative of adaptation at other codon positions.
There are other amino acid changes that are similar to the lysine to as-
paragine (K to N) change in that they can be achieved by two different nu-
cleotide changes. We provide a list of these amino acid changes (limited to
those changes that are one mutational step away) in Suppl. Table S2. One of
the changes on this list is the methionine to leucine (M to L) change, which is
relevant for drug resistance in HIV. The M46L change in the Protease gene leads
to resistance to certain Protease Inhibitors. A six-patient dataset from 1997 [20]
provides two examples of the fixation of the M46L change from wildtype (ATG)
to resistant (TTG or CTG). In one of these two patients, we observe a mixture
of the TTG and CTG codons (thus a soft sweep) whereas in the other patient
we only observe the TTG codon (potentially a hard sweep, see Suppl. Figure
S3). Of the other four patients, two did not fix the M46L mutation and two
fixed it at the same time as another resistance mutation. It is difficult to draw
conclusions based solely on the data from this study because it consists of only 6
patients [20], but they do provide independent support for our observation that
drug resistance mutations in HIV fix by means of both soft and hard sweeps.
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An interesting question is whether the resistance mutations that fix stem
from standing genetic variation or are due to de novo mutations during treat-
ment. If the resistance mutations stem from standing genetic variation, then
our estimate of Ne would reflect the pre-treatment effective population size,
whereas, if the mutations would be due to de novo mutation, our estimate
would reflect the effective population size during treatment. We compared the
times of occurrence of soft and hard sweeps relative to the onset of treatment
and found that these were statistically indistinguishable. There are three possi-
ble explanations for this observation. First, almost all observed sweeps are due
to standing genetic variation, and our estimate of Ne reflects the pre-treatment
population. Second, almost all sweeps are due to new mutations and our esti-
mate reflects only the on-treatment Ne. Third, sweeps we observe originated
from both standing genetic variation and de novo mutation, but the start of
the treatment had no discernible effect on the effective population size, and our
estimate reflects both the pre-treatment and on-treatment population size.
We currently have no statistical power to distinguish between these three
possibilities, and so it is possible that, if the second explanation is true, the
pre-treatment population size is much larger than our estimate. However, some
of the sweeps we observed occurred very early during treatment (within one
or two months), and it seems likely that at least these early sweeps are due
to standing genetic variation (see also [21]). Note that, counter to intuition,
whether mutations stem from the standing genetic variation or not does not
affect the expected number of origins in a sample (see Suppl. Figure S4 and [4]).
Our estimate of Ne is similar to earlier estimates that were also based on
resistance mutations [9] and other beneficial mutations [10]. Our approach may
be viewed as a combination of these two previous approaches. Rouzine and
Coffin [10] tested whether a recombinant or double mutant genotype is present,
given that two beneficial mutations are sweeping through the population at the
same time. Similar to a second mutation that leads to a soft sweep, a double
mutant or recombinant can only occur in a population with sufficiently high
mutational or recombinational input, so that the frequency of such a genotype
in a sample permits the estimation of the mutational or recombinational input.
Frost et al [9] used inferred pre-treatment frequencies of two resistance mutations
at the same codon (RT M184I and M184V) to estimate the effective population
size. They found that the two mutations were present at different pre-treatment
frequencies in seven patients. In a very large population, the frequency of such
mutations would be close to the expected frequency (µ/s) in every patient, but
in smaller populations frequencies vary stochastically, and the spread in the
observed frequencies can be used to obtain an upper bound for the population
size.
Our estimate of the supply rate of resistance mutations is much lower than
would be expected if the effective population size were equal to the number of
virus-infected cells in the body, which is estimated to be 108 [7,8]. At the same
time, it is much higher than estimates of the effective population size based on
the level of diversity at synonymous sites (assuming neutrality of synonymous
variation) which would be around 103 [6]. Next we discuss possible reasons for
7
these discrepancies.
Why is our estimate higher than Ne from synonymous di-
versity?
We propose three possible explanations for the large difference between our es-
timate based on the frequency of soft sweeps and the estimate based on the
traditional analyses of synonymous diversity. All three explanations may be
contributing to this difference. First, some synonymous mutations may be dele-
terious [22]. Second, positive and negative selection on linked sites (draft and
background selection) reduce diversity at synonymous sites, but may have a
weaker effect on beneficial mutations such as K103N. Our observation that the
fixation of drug resistance mutations is accompanied by a reduction in diversity
provides evidence for this explanation. Third, synonymous diversity may take a
long time to recover after a sweep or a bottleneck. We discuss the third option
in more detail and provide evidence from the data for this explanation.
We observe that diversity at both synonymous and non-synonymous sites
steadily recovers after the sweep (Figure 3). However, even after 6 to 18 months,
synonymous diversity remains significantly depressed, with a median reduction
of −53% (P = 0.01) compared to pre-sweep diversity, up from −66% (P = 10−4)
directly after the sweep. In contrast, after 6 to 18 months after the sweep, non-
synonymous diversity is fully recovered, with the median amount of diversity
increased by +5% (n.s.) compared to pre-sweep, up from −32% (P = 0.01)
directly after the sweep. Hence, even relatively infrequent selective sweeps can
keep synonymous diversity at a level much below the equilibrium.
The observation that stronger negative selection leads to faster recovery is
consistent with recent predictions about the approach of the distribution of
allele frequencies to stationarity at a single locus [23]. This effect is well known
in systems biology: stronger negative feedback leads to a faster the recovery
time [24]. A heuristic analysis (Text S1), similar to analyses in [25–27], shows
that neutral sites recover half of their diversity in roughly Ne generations while
deleterious sites recover half of their diversity in roughly 1/s generations, where
s is the strength of selection against deleterious mutations. Interestingly, for
realistic values of the mutation rate, the recovery time is independent of the
mutation rate (see Text S1 and Suppl. Figure S5).
The dynamics of how diversity recovers are likely not specific to HIV but
typical to any large population. In humans, for example, Europeans have re-
duced synonymous diversity, but a similar amount of non-synonymous diversity,
compared to Africans [28,29]. This is consistent with the explanation that non-
synonymous diversity has had enough time to recover since the out-of-Africa
bottleneck, but synonymous diversity has not. This observation leads to a
counterintuitive practical implication. Since non-synonymous diversity recovers
faster, it is usually closer to its equilibrium than synonymous diversity. Thus
non-synonymous sites may in fact be more useful for classical population genet-
ics inference than synonymous sites.
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Why is our estimate lower than the number of infected
cells?
HIV populations consist of a heterogeneous collection of genotypes, many of
which may carry deleterious and advantageous mutations. A new mutation
arises in one such genotype and is therefore linked, at least temporarily, to other
mutations already present in it. The probability that a new mutation eventually
fixes or goes extinct thus depends not only on its own selective effect but also
on the combined fitness of the genetic background in which it arose [30,31]. The
effects of linkage on the fates of new mutations are complex and comprise an
active area of research [30–39], but the qualitative picture is straightforward.
The fates of neutral, deleterious and weakly beneficial mutations are entirely
determined by the background in which they arise [31]: only mutations that
arise on high-fitness genotypes have a chance to persist in the population (Figure
4a, b). The number of segregating neutral mutations in such a population will
be small because high-fitness individuals comprise only a small fraction of the
population [30, 33, 34]. At the other extreme, adaptive mutations with very
large selective effects survive and spread irrespective of the genetic background
in which they arise (Figure 4c). The effective population size for such mutations
may be close to the census population size [13]. The effective population size
for mutations with intermediate effects is somewhere in between (Figure 4d).
The effective size we estimate from the K103N mutation is several orders
of magnitude smaller than the estimated census size. This could mean that
the distribution of fitnesses in the viral population due to ongoing positive and
negative selection is wide, so that even a highly beneficial mutation such as
K103N needs to appear in relatively fit genetic background to have a good
chance of survival. The width of the distribution of fitnesses in within-patient
HIV populations is currently unknown. Theory shows that the width of the
fitness distribution depends on the rates and typical effects of beneficial and
deleterious mutations and on the viral census size [30,39,40], quantities that are
difficult to estimate. Neher and Leitner recently estimated that at least 15%
of non-synonymous mutations have a selection coefficient exceeding 0.8% [41].
In another study, Batorsky et al concluded that the rate of adaptation of HIV
rate is consistent with an exponential distribution of fitness effects of adaptive
mutations with mean 0.5% [42]. If these estimates are accurate, they could
imply that the distributions of fitnesses in within-patient HIV populations are
narrow so that fixation of highly beneficial mutations like K103N should not be
affected by linked selection.
Other effects may help explain why the effective size of HIV is smaller than
the census size. For example, the treatment itself may reduce the population
size of the virus before resistance evolves. If this is true, then soft sweeps must
be especially common in patients who were treated with inferior drugs in the
1980s and 1990s, because early treatments were not as successful in reducing the
population size of the virus. If treatment reduces the effective population size,
then this would also mean that soft sweeps should be more common in patients
who fail early versus patients who fail later (after more time on treatment). We
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find no evidence for such an effect in the current data set (results not shown).
Alternatively, spatial population structure and epistatic effects may reduce the
effective population size for resistance mutations.
We obtained our population size estimate under the assumption—most cer-
tainly violated in reality at least to some extent—that all patients have the same
constant effective population size. Unfortunately, we do not have sufficient sta-
tistical power to relax this assumption. Longitudinal data with denser and
deeper sampling is required to study inter-patient and temporal heterogeneity
in viral adaptation.
Conclusions
We observe soft and hard sweeps in HIV, which leads to an estimated effective
population size relevant for adaptation of around 1.5 × 105. This number is
much higher than what the observed level of synonymous diversity suggests.
An important caveat of our approach is that we assume that the supply rate of
beneficial mutations is similar in all patients, which may not be true. Larger
samples are needed to estimate the patient-specific supply rate of adaptive mu-
tations. Our results show that neither synonymous diversity, nor the census
population size provide sufficient information to infer a population’s adaptive
potential, which explains, in part, why it is hard to predict whether and when
adaptive evolution will occur. Our finding that adaptive evolution in HIV is lim-
ited by the supply rate of beneficial mutations suggests that a relatively modest
reduction of the effective population size may help prevent the evolution of drug
resistance, and it is possible that the reduction of Ne that results from modern
combination therapy, does just that [21]. In addition, if the adaptive potential
of the virus is limited because a large proportion of the beneficial mutations land
on inferior genetic backgrounds, then the use of mutagenic drugs, in combina-
tion with standard antiretroviral drugs, should reduce the adaptive potential
of the virus [43]. Finally, our results confirm what has already been predicted
theoretically, that the idea of a single effective population that can be used to
describe different aspects of the behavior of a population does not work [13,44].
Material and Methods
Loss of diversity
Out of a larger dataset [12], we used viral sequences from patients for which
we had samples at two consecutive time-points that satisfy the following two
criteria. (1) At the first time-point, no known resistance mutations to any of the
drugs used in the trial was present at more than 30% frequency in the sample.
See below for the list of drugs and mutations. (2) At the next time-point, at
least one drug resistant allele increases in frequency by at least 70%. There were
30 such patients. In most cases (26 out of 30) the frequency of the mutations
changes from 0 to 100%. The four exceptions are patient 89 (mutation G190S
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changed from 0 to 75%), patient 168 (mutation K103N changed from 0 to
83%), patient 22 (mutation K103N changed from 134 to 100%, while mutation
V82A changed from 0 to 100%,), and patient 81 (mutation K103N changed
from 14 to 100%). In most cases (24 out of 30) only a single drug-resistance
mutation went to fixation (2 mutations in patients 22, 56, 87, 91, 154 and 166).
For details per patient, see supplementary table S1.
The patients were treated with Zidovudine, Lamivudine, Efavirenz and In-
dinavir [12]. There are many known mutations that confer resistance to one or
more of these drugs. We are interested in the fixation of the first resistance mu-
tation in a viral population. We used the following list of major drug-resistance
mutations (the number is the codon and the letter is the amino-acid that con-
fers resistance). Protease: 46IL, 82AFT, 84V; Reverse Transcriptase: 41L, 62V,
65R, 67N, 70R, 75I, 77L, 100I, 101P, 103N, 106MA, 108I, 116Y, 151M, 181CI,
184VI, 188LCH, 190SA, 210W, 215YF, 219QE, 225H [45].
Our dataset consists of coding sequences of the regions of the Pol gene that
encode for protease (all 297 basepairs) and reverse transcriptase (first 689 base-
pairs). We analyze separately all third codon position sites and all first and sec-
ond codon position sites. Most observed mutations at third codon position sites
have no effect on the amino acid, and we expect these synonymous mutations
to be neutral or nearly neutral. Throughout the paper, we refer to mutations
at first and second position sites as non-synonymous and mutations at third
position sites as synonymous. Most mutations at the first or second codon po-
sitions change the amino acid, and we expect that most such non-synonymous
mutations are selected against.
No change in genetic diversity was observed in 27 control intervals that also
started with drug susceptible virus but in which no fixation of drug resistant
amino-acids occurred (largest frequency change of drug resistant amino-acid in
these intervals was 30%).
We found no difference in pre-sweep diversity at third codon position sites
between hard sweep and soft sweep patients.
Recombination
To determine whether recombination affects the reduction of diversity, we split
the sequences into a part close to the selected site (less than 50, 100, or 200
basepairs distance from the selected site) and the complementary part far from
the selected site. We found no difference in the amount of diversity loss in the
close versus far sites. Earlier work suggests that selection may be so strong,
relative to the recombination rate, that the sweeps can affect the entire genome
[17,41].
Estimating the supply rate of resistance mutations
We can use the counts of the two beneficial alleles (AAT and AAC at the 103rd
amino acid of RT) in the post-sweep samples to estimate the the supply rate
of resistance mutations. We assume that the mutation rate µAAT to the AAT
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codon and the mutation rate µAAC to the AAC codon are equal to each other,
µAAT = µAAC ≡ µ. If Ne is the effective population size, then θ = 2Neµ, and
θ/2 is the total population-wide beneficial mutation rate, which we also call
“the supply rate of resistance mutations”.
Theory predicts that the population frequency x of the AAC allele follows
a beta-distribution with parameters (θ/2, θ/2) (see [4]). The number k of AAC
alleles in a sample of size n follows the binomial distribution with parameters
n and x. Thus, the likelihood of observing k1, . . . , kM AAC alleles in sam-
ples of size n1, . . . , nM in M patients is given by the product of beta-binomial
distributions,
L(k1, . . . , kM ; θ) =
M∏
i=1
(
ni
ki
)
B(ki + θ/2, ni − ki + θ/2)
B(θ/2, θ/2)
, (1)
where B(a, b) is the beta-function. By maximizing expression (1), we obtain the
maximum likelihood estimate θˆ = 0.62. The estimated supply rate of K103N
mutations is θˆ/2 = 0.31. The 95% bootstrap confidence interval for the supply
rate obtained by resampling patients with replacement is [0.17, 0.97].
We estimate the effective population size as θˆ/2µ. Because we only consider
the K103N mutation, µ ≈ 2×10−6 [19,46]. Note that this number is lower than
the typical per site mutation rate, because most (∼ 85%) mutations in HIV are
transitions, whereas the A to C and A to T mutations that create the K103N
change, are both transversions. We thus estimate the effective population size
to be 1.5× 105 (95% confidence interval [0.8× 105, 4.8× 105]).
For a given sample size and a given supply rate of beneficial mutations, we
can also predict the probability that the beneficial mutation originates from 1,
2 or more mutational origins following [4]. For a sample of size 6 (the median in
the dataset) and the estimated supply rate of beneficial mutations of 0.31, the
predicted probability that all observed beneficial alleles in the sample stem from
a single origin is 30%, the probability that they stem from 2 origins is 43%, 3
origins: 22% and 4, 5 or 6 origins: 6%. This shows that even if the supply rate
is exactly the same in all populations, the observed sweep signature can vary
widely.
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Selective sweep in patient 058    
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Figure 1. Soft sweep in patient 058. Codon AAA coding for lysine at
position 103 was replaced by day 28 with a mixture of codons AAT and AAC
both coding for asparagine which confers resistance to NNRTI drugs. Genetic
diversity close to the selected site was not significantly reduced. The plot
shows only the polymorphic sites among the first 500 basepairs of the reverse
transcriptase region. Each row represents a sequenced viral isolate. Each
column represents a polymorphic site, with the derived synonymous and
non-synonymous polymorphisms shown in black and orange respectively.
Codon 103 is shown explicitly. It is grey when coding for lysine (susceptible)
and blue when coding for asparagine (resistant). The responsible mutations
are colored pink (T) and yellow (C).
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Selective sweep in patient 086    
sequence
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Figure 2. Putatively hard sweep in patient 086. Codon AAA coding at
position 103 was replaced by day 84 with codon AAT. Genetic diversity
around the selected site was strongly reduced. Notations as in Figure 1.
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Nucleotide diversity over time
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Figure 3. Nucleotide diversity over time in 30 patients. Nucleotide
diversity at synonymous (black) and non-synonymous (red) sites. The time
point “before fixation” is the last sample in each patient taken before the
observed fixation of a resistance mutation. The time point “immediately after
fixation” is the first sample in each patient in which the drug resistance
mutation is observed to be fixed. The third and the fourth time points denote
samples in each patient taken 1–180 days and 181–700 days after the observed
fixation of the resistance mutation respectively. Dashed horizontal lines show
the nucleotide diversity at synonymous (black) and non-synonymous (red)
sites at the time point “before fixation” to provide a reference for subsequent
time points.
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Figure 4. Fates of mutations in a heterogeneous population. This
schematic shows the fates (“fix”, fixation; “ext” extinction) of mutations with
different selective effects, as indicated in each panel, depending on the fitness
of the genotype they occur in. The light gray area shows the distribution of
fitnesses in the population. Small gray arrows show how natural selection
changes the distribution of genotypes: fitter than average genotypes increase
in frequency, less fit than average genotypes decrease in frequency. Colored
arrows show the effect size of new mutations: neutral mutations (effect size 0)
are shown in blue (panel a.), adaptive mutations (effect size > 0) are shown in
orange (panels b. weakly beneficial, panel c. strongly beneficial, panel d.
intermediate beneficial effect). Mutations that are destined for fixation
(extinction) are shown with solid (dashed) arrows. Mutations with a large
beneficial effect can fix if they arise in any background (panel c), whereas
mutations with a small beneficial effect can fix only if they arise in a very fit
background (panels a., b., and d.). The resulting effective population size for
mutations with a given effect size is shown as red shading.
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Supplementary Text S1. TextS1.pdf Recovery of diversity. In this
section, we analyze how genetic diversity recovers after a selective sweep in the
data and in a mathematical model.
Recovery of diversity
Because the patients were followed for approximately one year (median, appr.
200 generations [47]), it is possible to determine whether the viral populations
in the patients recover from the observed selective sweep. We binned the ob-
servations in three bins. Bin 1: directly after the fixation event (the day the
resistance mutation was detected, most likely this is shortly after it was fixed
and allowed an increase in viral load). Bin 2: observations between 1 and 180
days after the fixation was observed. Bin 3: between 181 and 700 days after the
fixation was observed. If a second drug resistance mutation became fixed in the
virus of a patient the sample in which this was observed and any later samples
were removed from the analysis.
In order to model the recovery of heterozygosity, we assume that during the
periods between sweeps of resistance mutations there is no positive or balanc-
ing selection, only mutation, random drift, and negative selection. We further
assume that negative selection on linked sites simply reduces the effective pop-
ulation size and may thus be captured by the random drift term in standard,
single-locus population-genetic models [48].
We assume two alleles: the ‘non-mutant’ A1 and the ‘mutant’ A2, with
relative fitnesses 1 and 1−s, respectively. With probability u A1 mutates to A2,
and with probability v A2 mutates to A1. Reproduction occurs according to the
haploid Wright-Fisher model, with non-overlapping generations and constant
population size N . If the current frequency of the mutant is x, then
x′′ =
x(1− s)(1− v) + (1− x)u
1− sx (2)
gives the frequency after selection and mutation. The number of mutants in the
next generation is binomial with parameters N and x′′, so that its frequency X
has expectation E[X] = x′′ and variance Var[X] = x′′(1− x′′)/N .
We are interested in the recovery of heterozygosity, and so consider
E[∆H] = E[2X(1−X)− 2x(1− x)] (3)
= 2x′′(1− x′′)
(
1− 1
N
)
− 2x(1− x). (4)
where the (1 − 1N ) term reflects the loss of heterozygosity due to identity by
descent (coalescence). We seek a simple heuristic formula that will aid in un-
derstanding the recovery of heterozygosity after a selective sweep. Assuming
that s, u, v, and 1/N are all small, which is appropriate for HIV, and further
assuming that the mutant frequency x is small, gives
E[∆H] ≈ 2u−
(
s+ 3u+ v +
1
N
)
H, (5)
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in which H = 2x(1 − x) ≈ 2x. We apply this result to the recovery of
heterozygosity at synonymous and non-synonymous sites heuristically using a
continuous-time approximation.
For synonymous sites, we assume that all mutations are neutral and that
u, v  1N . Then dHdt = 2u − 1NH, and if H(0) = 0, we have H(t) = 2Nu(1 −
exp(−t/N)). The response time, thalf , defined as the time it takes for H to
recover 50% of its loss of diversity, can be found by solving 0.5 = exp(−thalf/N)
giving thalf = N log 2. Note that under the assumption u, v  1N , the response
time is independent of the mutation rates and it is possible to estimate N
independently from u. For non-synonymous sites, we assume that selection
is stronger than both random drift and mutation, or and solve dHdt = 2u −
sH to obtain H(t) = 2(u/s)(1 − exp(−st)). In this case the response time
is thalf = s
−1 log 2. Thus s may be estimated independently from u. These
expressions for thalf illustrate that non-synonymous sites will recover faster
than synonymous sites if s > 1N . Suppl Figure 2 shows that these approximate,
heuristic expressions agree well with simulations as long as the mutation rate is
sufficiently small.
Our conclusions are in agreement with previous results by Gordo and Dis-
onisio [27] who described that more deleterious mutations approach mutation-
selection equilibrium faster than less deleterious mutations. Song and Steinru¨cken
[23] have recently described a method for studying the approach to stationarity
of the entire distribution of allele frequencies, and also illustrated that recovery
is faster when mutations are more deleterious.
22
Supplementary Figure S1. Nucleotide diversity reduction due to
different fixations. Nucleotide diversity at all sites. The patients are split in
four groups: the first group in which one codon of the K103N was fixed
(K103N one codon), a group in which a mixture of two codons of K103N was
fixed (K103N two codons), a group in which a different amino acid change was
fixed (Other mutation) and a group in which two resistance mutations were
fixed (Two mutations). Large red circles show the median for each group. The
shape of the points reflects the treatment the patient was on: circle: treated
with indinavir then later switched to efavirenz combination therapy, triangle:
treated with indinavir + efavirenz, plus-sign: treated with indinavir, cross:
treated with ZDV/3TC + efavirenz diamond: treated with ZDV/3TC, later
switched to efavirenz combination therapy.
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Selective sweep in patient 089    
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Supplementary Figure S2. Soft and hard sweep example. A. Soft
sweep in patient 089. Codon GGC coding for glysine at position 190 was
replaced by day 56 by codon AGC coding for serine, which confers resistance
to NNRTI drugs. The G190S mutation appears to have occurred on at least
two different backgrounds. As predicted by theory [18], the site is embedded in
a region of high linkage disequilibrium. The different haplotypic backgrounds
are indicated by differently colored pastel backgrounds. Genetic diversity was
reduced by 38%. The plot shows the polymorphic sites in the reverse
transcriptase region, excluding all singletons. Each row represents a sequenced
viral isolate. Each column represents a polymorphic site, with the derived
synonymous and non-synonymous polymorphisms shown in black and orange
respectively. Codons 103, 108, 188, 190 and 225 are all linked to NNRTI
resistance and are shown explicitly. They are grey when when in the
susceptible state and blue when in the resistant state. Mutations in these
codons are colored pink.
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Selective sweep in patient 159    
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Supplementary Figure S2. Soft and hard sweep example. B. Hard
sweep in patient 159. Codon GGA coding for glysine at position 190 was
replaced by day 225 by codon GCA coding for alanine, which confers
resistance to NNRTI drugs. The G190A mutation appears to have occurred on
at least a single haplotypic background. Genetic diversity was reduced by
67%. The plot shows the polymorphic sites in the reverse transcriptase region,
excluding all singletons. Each row represents a sequenced viral isolate. Each
column represents a polymorphic site, with the derived synonymous and
non-synonymous polymorphisms shown in black and orange respectively.
Codons 190 is shown explicitly. It is colored grey when when in the susceptible
state and blue when in the resistant state. Mutations in this codon are colored
pink.
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Selective sweep in patient 6 (Zhang 1997)
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Supplementary Figure S3. Soft and hard sweep example. A. Soft
sweep in patient 6 [20] Codon ATG coding for methionine at position 46 was
replaced in 1993/10 by codons CTG and TTG, both coding for leucine, which
confers resistance to Protease inhibitor drugs. The plot shows the polymorphic
sites in the protease region, excluding all singletons. Each row represents a
sequenced viral isolate. Each column represents a polymorphic site, with the
derived synonymous and non-synonymous polymorphisms shown in black and
orange respectively. Codons 10, 46, 71 are linked to Protease Inhibitor drug
resistance and shown explicitly. They are colored grey when when in the
susceptible state and blue when in the resistant state. Mutations in these
codons are colored pink. The viral load in this patient was around 106 before
treatment, it went down approximately 1.5 log values and rebounded quickly
to its original level (see figure 1 in [20]).
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Selective sweep in patient 3 (Zhang 1997)
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Supplementary Figure S3. Soft and hard sweep example. B. Hard
sweep in patient 3 [20] Codon ATG coding for methionine at position 46 was
replaced in 1994/02 by codon TTG, which codes for leucine, which confers
resistance to Protease inhibitor drugs. The plot shows the polymorphic sites in
the protease region, excluding all singletons. Each row represents a sequenced
viral isolate. Each column represents a polymorphic site, with the derived
synonymous and non-synonymous polymorphisms shown in black and orange
respectively. Codons 10, 46, 71 are linked to Protease Inhibitor drug resistance
and shown explicitly. They are colored grey when when in the susceptible
state and blue when in the resistant state. Mutations in these codons are
colored pink. The viral load in this patient was slightly higher than 105, it
went down to below the detection limit of 104 and stayed low for more than
six months, after which it rebounded (see figure 1 in [20]).
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Supplementary Figure S4. Probability of a single origin (hard
sweep) in a sample of size 6. Simulation results show that the number of
origins is independent of whether or not standing genetic variation is involved,
and if standing genetic variation is involved, the number of origins is
independent of the selection coefficient of the allele before or after the start of
treatment. The horizontal line denotes the theoretical expectation [4]. The
bars denote the probability that a sample of size six consists of just one origin,
averaged over 1000 runs. The population size in the simulations is 150, 000
and the mutation rate 2× 10−6, so that θ/2 = 0.3.
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Supplementary Figure S5. Predicted response time. Comparison of
the response time thalf , defined as the time it takes for H to recover 50% of its
loss of diversity, from the heuristic model and from simulations. Dashed lines
show thalf = s
−1 log(2) (for s > 0) or thalf = N log(2) (for s = 0). Dots
display averages over 1000 simulations of a haploid Wright-Fisher population
with N = 104 individuals for each pair of values of u and s. In all cases, v = u.
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Supplementary Table S1. Patient details. For each of the (a.) 30 patients
that were included in the analysis, this table gives (b.) the codon(s) of the
resistance mutation(s) that occurred (with nucleotide changes indicated for all
mutations except the 103rd codon of RT, P82 indicates the 82nd codon in Pro-
tease, all other codons are in RT), (c.) the level of diversity before and (d.)
after the sweep, (e.) the sample size of the first sample after the sweep, (f.)
the number of AAC and (g.) AAT alleles observed in the first sample after the
sweep, and (h.) the treatment the patient was receiving.
a.
pat
ient
b. resistance codon /
mutation
c.
div
pre
d.
div
after
e.
sam.
size
f.
103
AAC
g.
103
AAT
h. treatment
5 103 0.018 0.006 4 3 1 IDV then EFV comb therapy
7 103 0.008 0.008 6 6 0 IDV + EFV
12 103 0.024 0.016 2 1 1 IDV + EFV
13 103 0.018 0.002 7 0 7 IDV + EFV
20 P82 (GTC → ACC) 0.017 0.010 6 0 0 IDV
22 103, P82 (GTC →
GCC)
0.022 0.005 4 4 0 IDV + EFV
24 103 0.012 0.017 7 5 2 IDV then EFV comb therapy
32 103 0.012 0.004 8 8 0 IDV + EFV
44 103 0.019 0.017 3 3 0 IDV + EFV
56 103, 62 (GGC→ GTC) 0.012 0.004 2 2 0 IDV + EFV
57 103 0.010 0.013 6 3 3 IDV + EFV
58 103 0.012 0.016 7 4 3 IDV + EFV
63 103 0.012 0.005 7 7 0 IDV + EFV
66 103 0.016 0.003 5 5 0 IDV + EFV
70 P82 (GTC → GCC) 0.017 0.007 6 0 0 IDV then EFV comb therapy
71 103 0.018 0.005 7 0 7 IDV + EFV
77 103 0.025 0.002 7 0 7 IDV + EFV
81 103 0.012 0.010 8 7 1 IDV + EFV
83 190 (GGA → GCA) 0.015 0.008 8 0 0 IDV + EFV
86 103 0.029 0.003 6 0 6 IDV + EFV
87 103, P82 (GTC →
GCC)
0.011 0.006 8 7 1 IDV then EFV comb therapy
89 190 (GGA → AGC) 0.020 0.012 8 0 0 IDV + EFV
91 103, P82 (GTC →
GCC)
0.012 0.020 2 2 0 IDV then EFV comb therapy
95 103 0.012 0.004 6 6 0 IDV then EFV comb therapy
154 103, 100 (TTA →
ATA)
0.020 0.008 7 7 0 ZDV/3TC + EFV
159 190 (GGA → GCA) 0.015 0.005 6 0 0 ZDV/3TC + EFV
166 103, 184 (ATG →
GTG)
0.009 0.011 4 4 0 ZDV/3TC + EFV
167 184 (ATG → GTG) 0.015 0.026 7 0 0 ZDV/3TC, then EFV comb
therapy
168 103 0.024 0.014 6 2 3 ZDV/3TC + EFV
171 184 (ATG → GTG) 0.024 0.008 2 0 0 ZDV/3TC + EFV
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Supplementary Table S2. List of amino acid changes that can be achieved
by two or more single nucleotide changes and thus allow the observation of soft
sweeps at the beneficial site itself. In almost all cases, the relevant mutations
are transversions (TV). In the last three cases (marked with an asterisk), one
of the mutations is a transition (TS). In these cases, the difference in muta-
tion rates (higher for transitions) will make it less likely to observe a soft sweep.
a.
From
amino
acid
b.
From
codon
c.
To
amino
acid
d.
To codons
e.
Relevance for HIV
drug resistance
K AAA N AAC (TV), AAT (TV) relevant for RT
K103N
M ATG L CTG (TV), TTG (TV) relevant for RT M41L
and PRO M46L
C TGC S AGC (TV), TCC (TV)
C TGT S AGT (TV), TCT (TV)
D GAC E GAA (TV), GAG (TV)
D GAT E GAA (TV), GAG (TV)
E GAA D GAC (TV), GAT (TV)
E GAG D GAC (TV), GAT (TV)
G GGA R AGA (TS), CGA (TV)
G GGG R AGG (TS), CGG (TV)
H CAC Q CAA (TV), CAG (TV)
H CAT Q CAA (TV), CAG (TV)
I ATA L CTA (TV), TTA (TV)
K AAG N AAC (TV), AAT (TV)
L TTA F TTC (TV), TTT (TV)
L TTG F TTC (TV), TTT (TV)
N AAC K AAA (TV), AAG (TV)
N AAT K AAA (TV), AAG (TV)
Q CAA H CAC (TV), CAT (TV)
Q CAG H CAC (TV), CAT (TV)
R AGA S AGC (TV), AGT (TV)
R AGG S AGC (TV), AGT (TV)
T ACC S TCC (TV), AGC (TV)
T ACT S TCT (TV), AGT (TV)
V GTA L CTA (TV), TTA (TV)
V GTG L CTG (TV), TTG (TV)
W TGG C TGC (TV), TGT (TV)
W TGG R AGG (TV), CGG (TS)
S AGC R CGC (TV), AGA (TV), AGG (TV)
S AGT R CGT (TV), AGA (TV), AGG (TV)
F TTC L CTC (TS), TTA (TV), TTG (TV) *
F TTT L CTT (TS), TTA (TV), TTG (TV) *
M ATG I ATA (TS), ATC (TV), ATT (TV) *
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